Tango Therapeutics to Showcase Innovations in Healthcare
BOSTON, in an exciting announcement, Tango Therapeutics, Inc. (NASDAQ: TNGX) has revealed plans for participation in a major upcoming conference that highlights advancements in healthcare. Dr. Barbara Weber, the dynamic President and CEO of Tango Therapeutics, is set to engage in a fireside chat at the renowned Goldman Sachs Global Healthcare Conference.
Fireside Chat Details
This engaging conversation is scheduled for an afternoon slot, specifically on a Tuesday, with a focus on 3:20 to 3:55 PM ET. Attendees can look forward to insights from Dr. Weber as she discusses the innovative approaches Tango Therapeutics is pioneering in the realm of cancer treatment. This presentation will be streamed live for those interested in real-time updates and insights.
Access to Live Webcast and Replay
The live webcast will be accessible under the "Events & Presentations" section on the Company’s website, making it easy for investors and stakeholders to tune in. After the event, a replay will be available on the Company’s site for a generous period of 90 days, allowing those who may have missed it to catch up on the critical discussions presented.
About Tango Therapeutics
Tango Therapeutics stands at the forefront of biotechnology, representing a clinical-stage company that is passionately dedicated to the quest for novel drug targets. With a strong commitment to enhancing precision medicine, Tango Therapeutics focuses on the treatment of cancer. Central to their approach is the genetic principle of synthetic lethality, which serves as a foundation for the development of targeted therapies that effectively aim at pivotal cancer targets.
Innovative Methods in Cancer Treatment
Through a patient-centered approach, Tango Therapeutics emphasizes collaboration and innovation. They are dedicated to exploring new horizons in cancer treatment, ensuring that every step is deeply rooted in patient care and personal experience. Their methodologies are designed not just to treat but to revolutionize cancer therapies.
Company Contact Information
For those seeking further information, Tango Therapeutics encourages inquiries from both investors and media representatives. Elizabeth Hickin leads the dialogue, and interested parties can reach out via the provided email addresses, IR@tangotx.com for investor relations, and media@tangotx.com for media inquiries.
Frequently Asked Questions
What is the purpose of Tango Therapeutics' participation in the conference?
The participation aims to showcase innovative advancements in cancer treatment and facilitate discussions on precision medicine.
Who will represent Tango Therapeutics at the Goldman Sachs conference?
Dr. Barbara Weber, the President and CEO, will be the representative leading the fireside chat.
How long will the live webcast be available for viewing?
The live webcast will be accessible on the Company’s website for 90 days after the event for replay.
What is synthetic lethality as it relates to Tango Therapeutics’ research?
Synthetic lethality is a genetic principle utilized by Tango Therapeutics to discover and develop targeted cancer therapies aimed at critical targets.
How can investors and media contact Tango Therapeutics for more information?
Inquiries can be directed to Elizabeth Hickin via email at IR@tangotx.com for investors and media@tangotx.com for media contacts.